Triantafyllias, Konstantinos; Heller, Caroline; de Blasi, Michele et al.
A Sex Difference in HandScan Scores in Rheumatoid Arthritis Patients and Controls? An Ongoing Analysis of the Sex Difference and Other Potential Confounders ReplyJOURNAL OF RHEUMATOLOGY. Bd. 48. H. 6. 2021 S. 951-951
Castven, Darko; Czauderna, Carolin; Becker, Diana et al.
Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes-Associated Protein 1 Activation and Transient Expansion of Stem-Like Cancer CellsHEPATOLOGY COMMUNICATIONS. Bd. 6. H. 5. 2021 S. 1140-1156
Zander, T.; Kelly, R. J.; Ajani, J. A. et al.
Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577ONCOLOGY RESEARCH AND TREATMENT. Bd. 44. 2021 S. 80-81
Kelly, Ronan Joseph; Ajani, Jaffer A.; Kuzdzal, Jaroslaw et al.
Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Kelly, Ronan J.; Ajani, Jaffer A.; Kuzdzal, Jaroslaw et al.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerNEW ENGLAND JOURNAL OF MEDICINE. Bd. 384. H. 13. 2021 S. 1191-1203
Moehler, M.; Ajani, J. A.; Kuzdzal, J. et al.
Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577ANNALS OF ONCOLOGY. Bd. 32. 2021 S. S1045-S1046
Kelly, R. J.; Ajani, J.; Kuzdzal, J. et al.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Following Neoadjuvant Chemoradiation Therapy: First Results of the CheckMate 577 StudyANNALS OF SURGICAL ONCOLOGY. Bd. 28. H. SUPPL 1. 2021 S. S41-S42
Hagstrom, Hannes; Adams, Leon A.; Allen, Alina M. et al.
Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus StatementHEPATOLOGY. Bd. 74. H. 1. 2021 S. 474-482
Schneider, E.; Lautem, A.; Boedecker, S. C. et al.
AFTER FULL (TWO TIMES) VACCINATION WITH COMIRNATY (R), 28% OF LIVER OR KIDNEY TRANSPLANTED PATIENTS HAD NO T-CELL-REACTIVITY AGAINST SARS-COV-2 SPECIFIC ANTIGENSTRANSPLANT INTERNATIONAL. Bd. 34. 2021 S. 33-34
Woelfinger, Pascal; Hauptrock, Beate; Kriege, Oliver et al.
Alloimmune Myositis as Paraneoplastic Complication of an Oral Squamous Cell Carcinoma After Severe Chronic Graft vs Host Disease or a Manifestation of Chronic Graft vs Host Disease? A Case Report and Literature DiscussionTRANSPLANTATION PROCEEDINGS. Bd. 53. H. 4. 2021 S. 1365-1368
Kreft, Andreas; Hippe, Katrin; Wagner-Drouet, Eva Maria et al.
An investigation of the diagnostic, predictive, and prognostic impacts of three colonic biopsy grading systems for acute graft versus host diseasePLOS ONE. Bd. 16. H. 8. 2021
Zarkovic, M.; Wiersinga, W.; Perros, P. et al.
Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatmentJOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. Bd. 44. H. 2. 2021 S. 371-378
Schwaegermann, Marie-Kristin; Schranz, Melanie; Moehler, Markus et al.
Any progress in informed consenting for cancer treatment? Results from a cross sectional analysis at a comprehensive cancer centerJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. Bd. 147. H. 7. 2021 S. 2117-2126
Kaps, L.; Ahlbrand, C. J.; Gadban, R. et al.
Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive carePLOS ONE. Bd. 16. H. 4. 2021
Munoz-Martinez, Sergio; Sapena, Victor; Forner, Alejandro et al.
Assessing the impact of COVID-19 on liver cancer management (CERO-19)JHEP REPORTS. Bd. 3. H. 3. 2021
Galle, Peter R.; Finn, Richard S.; Cheng, Ann-Lii et al.
Assessment of the impact of anti-drug antibodies on PK and clinical outcomes with atezolizumab plus bevacizumab in HCC.CANCER RESEARCH. Bd. 81. H. 13. 2021
Labenz, Christian; Nagel, Michael; Kaemper, Paula et al.
Association Between Serum Levels of Neurofilament Light Chains and Minimal Hepatic Encephalopathy in Patients With Liver CirrhosisCLINICAL AND TRANSLATIONAL GASTROENTEROLOGY. Bd. 12. H. 10. 2021
Engel, Sinah; Boedecker, Simone; Marczynski, Paul et al.
Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosusTHERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. Bd. 14. 2021
Moeckel, Tamara; Basta, Fabio; Weinmann-Menke, Julia et al.
B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)AUTOIMMUNITY REVIEWS. Bd. 20. H. 2. 2021
Furie, Richard; Houssiau, Frederic; Lightstone, Liz et al.
Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus NephritisARTHRITIS & RHEUMATOLOGY. Bd. 73. 2021 S. 3068-3070
Armandi, Angelo; Schattenberg, Jorn M.
Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary ApproachesNUTRIENTS. Bd. 13. H. 6. 2021
Vali, Yasaman; Lee, Jenny; Schattenberg, Jorn et al.
BIOMARKER SCREENING STRATEGIES TO IDENTIFY FIBROSING STEATOHEPATITIS CASES FOR CLINICAL TRIAL RECRUITMENT IN NAFLDHEPATOLOGY. Bd. 74. 2021 S. 934A-936A
Vali, Yasaman; Lee, Jenny; Schattenberg, Joern M. et al.
Biomarker screening strategies to identify fibrosing steatohepatitis cases for clinical trial recruitment in NAFLDJOURNAL OF HEPATOLOGY. Bd. 75. 2021 S. S568-S569
Gehrke, Nadine; Straub, Beate; Woerns, Marcus-Alexander et al.
Blockade of IL-1 signaling in hepatocytes reduces tumor growth in a mouse model of NAFLD-related HCCJOURNAL OF HEPATOLOGY. Bd. 75. 2021 S. S599-S600
Tilch, Marie-Kristin; Galle, Peter R.; Schattenberg, Joern M. et al.
Burden of depression and anxiety disorders per disease codes in patients with lymphoma in GermanySUPPORTIVE CARE IN CANCER. Bd. 30. H. 3. 2021 S. 2387-2395